# Ceribell, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Ceribell, Inc.).

## Overview

Ceribell, Inc. is a medical technology company built around a point-of-care EEG platform for acute care settings. Its Ceribell System combines portable hardware, disposable Wearables, and AI-powered software to help clinicians detect and monitor seizures faster than conventional EEG workflows. The company is initially focused on non-convulsive status epilepticus and other serious neurological conditions in hospitals, especially ICU and emergency department environments. Ceribell sells primarily in the United States and has deployed its system at more than 600 hospitals, ranging from academic medical centers to community hospitals. Its business model is recurring, with revenue coming from disposable product usage and monthly software/subscription access.

## Products & services

• Ceribell System point-of-care EEG platform
• Disposable Wearables / headbands for single-patient use
• Clarity software subscription and portal access
• Recorders and related monitoring hardware
• AI-powered seizure detection and monitoring algorithms
• Hospital onboarding, training, and technical integration support

- **Disposable Wearables** (55%) — Single-use headbands/Wearables sold for patient EEG monitoring in acute care.
- **Subscription Software and Portal** (35%) — Monthly access to Clarity, recorders, and the cloud-based portal.
- **Monitoring Hardware** (10%) — Reusable recorders and related hardware used with the Ceribell System.

- Ceribell System point-of-care EEG platform
- Disposable Wearables / headbands for single-patient use
- Clarity software subscription and portal access
- Recorders and related monitoring hardware
- AI-powered seizure detection and monitoring algorithms
- Hospital onboarding, training, and technical integration support

## Customers

Ceribell sells mainly to acute care hospitals that need faster seizure detection and continuous EEG monitoring without the operational burden of conventional EEG systems. The core buyers are ICU and emergency department teams, including neurologists, intensivists, and hospital administrators who want quicker diagnosis and better workflow efficiency. Academic medical centers are important because they often adopt new clinical technologies early and help build evidence, while community hospitals value ease of deployment and access to specialist-level monitoring. The company also has a growing opportunity in Veterans Administration hospitals following FedRAMP High authorization. Customer retention matters because hospitals subscribe on recurring terms and can generally terminate or not renew with short notice.

- **Acute care hospitals** (primary) — Buy the Ceribell System to detect and monitor seizures in ICU and emergency settings where conventional EEG is slow or hard to deploy.
- **Academic medical centers** (secondary) — Adopt the platform early, use it for complex neurological cases, and help validate clinical utility.
- **Community hospitals** (primary) — Use the system because it is portable and easier to implement than traditional EEG infrastructure.
- **Veterans Administration hospitals** (emerging) — Potential buyers following FedRAMP High authorization, expanding access to a large federal hospital network.

- Acute care hospitals buying EEG tools for ICU and ED seizure evaluation
- Neurologists and intensivists using the system to speed diagnosis
- Hospital administrators seeking workflow efficiency and better economics
- Academic medical centers that adopt early and support clinical evidence
- Community hospitals that need portable EEG without specialist infrastructure
- Veterans Administration hospitals enabled by FedRAMP High authorization

## Geography

Ceribell’s commercial business is concentrated in the United States, where it sells through a direct sales organization. The company manufactures its system in Sunnyvale, California, which makes U.S. operations central to both supply and commercialization. Its supply chain is globally exposed because Wearables are sourced from third-party manufacturers in China and Vietnam, while recorder components are procured from various suppliers before final assembly in California. The company’s FedRAMP High authorization also creates a pathway into approximately 170 Veterans Administration hospitals in the U.S. At present, the business is primarily domestic, but regulatory approvals in additional geographies or indications could broaden its footprint over time.

- United States is the core sales market and the only disclosed commercial market
- Sunnyvale, California is the manufacturing and final assembly location
- Wearables are sourced from third-party manufacturers in China and Vietnam
- Recorder components are procured globally and shipped to California for assembly
- FedRAMP High authorization opens access to Veterans Administration hospitals
- Future expansion depends on regulatory approvals in additional geographies

## Strategy

Ceribell’s strategy is to make its system the standard of care for seizure detection in acute care hospitals. The company is prioritizing new account adoption, especially across the roughly 6,000 U.S. acute care facilities with ICUs and/or emergency departments that could benefit from rapid EEG access. It is also focused on expanding utilization within existing accounts through direct sales coverage, onboarding, and clinical education. A second strategic pillar is product and platform expansion, including technical validation for additional neurological indications beyond seizures. The company is using clinical evidence, AI-enabled workflow advantages, and federal authorization to strengthen its position against conventional EEG alternatives.

- **New hospital account acquisition** (short-term) — Growth depends on converting more acute care facilities to the Ceribell workflow.
- **Increase utilization in existing accounts** (short-term) — Recurring revenue rises when hospitals use more Wearables and maintain subscriptions.
- **Platform expansion beyond seizures** (medium-term) — Additional indications could enlarge the addressable market and reduce dependence on one use case.
- **Federal and institutional market access** (medium-term) — Regulatory and procurement approvals can unlock large hospital systems with centralized buying.

- Expand adoption into new acute care hospital accounts
- Increase utilization within existing hospital customers
- Use clinical evidence to support conversion from conventional EEG
- Leverage FedRAMP High authorization to access VA hospitals
- Invest in R&D for additional neurological indications
- Strengthen direct sales, onboarding, and hospital IT integration

## Risks

Ceribell’s revenue depends heavily on hospital adoption and continued subscription renewals, so slower-than-expected uptake or customer churn would directly pressure growth. The company also faces execution risk because its commercial model requires education, onboarding, and sustained clinical engagement to change hospital workflows. Supply chain concentration is a material risk: Wearables are sourced from third-party manufacturers in China and Vietnam, while final assembly occurs in Sunnyvale, so trade restrictions, supplier disruptions, or quality issues could affect availability and margins. As a medical device company, Ceribell is exposed to FDA and other regulatory changes that could delay new products or indications, and broader industry risks include reimbursement pressure, hospital budget constraints, and competition from conventional EEG systems or alternative monitoring technologies. Because the company is still loss-making and investing heavily in growth, it also faces financing and operating leverage risk if adoption or utilization does not scale as expected.

- **Customer adoption and retention risk** [high] — Revenue is driven by active accounts and Wearable usage, and hospitals can terminate subscriptions with short notice.
- **Supply chain concentration in China and Vietnam** [high] — Wearables are sourced from third-party manufacturers in China and Vietnam, creating exposure to trade restrictions and supplier disruptions.
- **Regulatory and FDA approval risk** [medium] — Future commercialization in additional geographies or indications depends on regulatory authorization.
- **Hospital workflow and reimbursement adoption risk** [medium] — The system requires clinical behavior change and budget approval in acute care settings.

- Hospital adoption may be slower than expected, limiting recurring revenue growth
- Existing customers can terminate or not renew subscriptions on short notice
- Commercial success depends on education and workflow change inside hospitals
- Supply chain dependence on China and Vietnam creates disruption and trade risk
- FDA and regulatory changes could delay new products or additional indications
- Hospital budget pressure and reimbursement dynamics may slow purchasing decisions
- Competition from conventional EEG and other monitoring solutions remains a threat

## Accounting

Ceribell’s revenue recognition is split between point-in-time product sales and over-time subscription revenue, which makes the mix between Wearables and software important for quarterly comparability. Wearable revenue is recognized when control transfers, while subscription revenue is recognized ratably over the contract term, so changes in customer usage or contract timing can shift reported revenue between periods. Management also notes that revenue fluctuates with the number of active accounts, the volume of Wearable usage, and seasonal patterns in ICU patient volumes, especially lower summer activity. Cost of revenue includes materials, labor, manufacturing overhead, third-party hosting fees, and shipping/tariff costs, so gross margin can move with product mix, supply chain costs, and utilization levels. As a growth-stage public company with operating losses and lease commitments, investors should also watch estimates around inventory, manufacturing capacity, and lease obligations, since these can affect expense timing and liquidity analysis.

- **Revenue recognition mix** — Quarterly revenue comparability
- **Seasonality and utilization** — Quarterly revenue and gross margin volatility
- **Cost of revenue allocation** — Gross margin
- **Operating lease commitments** — Cash flow and balance sheet analysis

- Point-in-time recognition for Wearables affects revenue timing
- Subscription revenue is recognized ratably over the contract term
- Revenue depends on active accounts and headband usage volume
- Seasonality in ICU volumes can create quarter-to-quarter swings
- Gross margin is sensitive to product mix and hosting/manufacturing costs
- Tariffs and shipping costs flow through cost of revenue
- Operating lease commitments and inventory assumptions affect liquidity analysis

---

*Last updated: 2026-04-28T14:26:24.072824+00:00*